Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Célèste Lebbé, Marc Pracht et al.|Clinical Cancer Research|2021Cited by 19
Phase I-II open label multicenter study of PD0332991 in <i>BRAF<sup>V600mut</sup></i> metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.Baptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Journal of Clinical Oncology|2019Cited by 5